Copanlisib

Copanlisib is filed as PI3K inhibitor. The sections below restate public label fields stored for this profile.

Class
PI3K inhibitor
Dosage forms
3 DOSAGE FORMS AND STRENGTHS For injection: 60 mg of copanlisib as a lyophilized solid in single-dose vial for reconstitution. For injection: 60 mg of copanlisib as a lyophilized solid in single-dose vial for reconstitution ( 3 ).

Approved uses

1 INDICATIONS AND USAGE ALIQOPA is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. Accelerated approval was granted for this indication based on overall response rate [see Clinical Studies ( 14.1 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ALIQOPA is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies ( 1 ). Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

How it works

12.1 Mechanism of Action Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. Copanlisib has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines. Copanlisib inhibits several key cell-signaling pathways, including B-cell receptor (BCR) signaling, CXCR12 mediated chemotaxis of malignant B cells, and NFκB signaling in lymphoma cell lines.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS • Infections: Monitor patients for signs and symptoms of infection. Withhold treatment for Grade 3 and higher infections until resolution ( 5.1 ). • Hyperglycemia: Start each infusion once optimal blood glucose control is achieved. Withhold treatment, reduce dose, or discontinue treatment depending on the severity and persistence of hyperglycemia ( 5.2 ). • Hypertension: Withhold treatment in patients until both the systolic blood pressure (BP) is less than 150 mmHg and the diastolic BP is less than 90 mmHg. Consider reducing dose if anti-hypertensive treatment is required. Discontinue in patients with BP that is uncontrolled or with life-threatening consequences ( 5.3 ). • Non-infectious pneumonitis (NIP): Treat NIP and reduce dose. Discontinue treatment if Grade 2 NIP recurs or in patients experiencing Grade 3 or higher NIP ( 5.4 ). • Neutropenia: Monitor blood counts at least weekly while under treatment. Withhold treatment until ANC ≥0.5 x 10 3 cells/mm 3 ( 5.5 ). • Severe Cutaneous Reactions: Withhold treatment, reduce dose, or discontinue treatment depending on the severity and persistence of severe cutaneous reactions ( 5.6 ). • Embryo-Fetal Toxicity: ALIQOPA can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception ( 5.7 , 8.1 , 8.3 ). 5.1 Infections Serious, including fatal, infections occurred in 19% of 317 patients treated with ALIQOPA monotherapy. The most common serious infection was pneumonia [see Adverse Reactions ( 6.1 )] . Monitor patients for signs and symptoms of infection and withhold ALIQOPA for Grade 3 and higher infection [see Dosage and Administration ( 2.4 )] . Serious pneumocystis jiroveci pneumonia (PJP) occurred in 0.6% of 317 patients treated with ALIQOPA monotherapy [see Adverse Reactions ( 6.1 )]. Before initiating treatment with ALIQOPA, consider PJP prophylaxis for populations at risk. Withhold ALIQOPA in patients with suspected PJP infection of any grade. If confirmed, treat infection until resolution, then resume ALIQOPA at previous dose with concomitant PJP prophylaxis [see Dosage and Administration ( 2.4 )] . Grade 1 or 2 cytomegalovirus (CMV) reactivation or infection has occurred in 0.97% of patients treated with ALIQOPA monotherapy. Monitor for CMV infection during treatment with ALIQOPA in patients with a history of CMV infection. For clinical CMV infection or viremia, withhold ALIQOPA until infection or viremia resolves. If ALIQOPA is resumed, administer at the previous dose and monitor patients for CMV reactivation by PCR or antigen test at least monthly [see Dosage and Administration ( 2.4 )]. 5.2 Hyperglycemia Grade 3 or 4 hyperglycemia (blood glucose 250 mg/dL or greater) occurred in 41% of 317 patients treated with ALIQOPA monotherapy [see Adverse Reactions ( 6.1 )] . Serious hyperglycemic events occurred in 2.8% of patients. Treatment with ALIQOPA may result in infusion-related hyperglycemia. Blood glucose levels typically peaked 5 to 8 hours post-infusion and subsequently declined to baseline levels for a majority of patients; blood glucose levels remained elevated in 17.7% of patients one day after ALIQOPA infusion. Of 155 patients with baseline HbA1c <5.7%, 16 (10%) patients had HbA1c >6.5% at the end of treatment. Of the twenty patients with diabetes mellitus treated in CHRONOS-1, seven developed Grade 4 hyperglycemia and two discontinued treatment. Patients with diabetes mellitus should only be treated with ALIQOPA following adequate glucose control and should be monitored closely. Achieve optimal blood glucose control before starting each ALIQOPA infusion. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of hyperglycemia [see Dosage and Administration ( 2.4 )] . 5.3 Hypertension Grade 3 hypertension (systolic 160 mmHg or greater or diastolic 100 mmHg or greater) occurred in 26% of 317 patients treated with ALIQOPA monotherapy [see Adverse Reactions ( 6.1 )] . Serious hypertensive events occurred in 0.9% of 317 patients. Treatment with ALIQOPA may result in infusion-related hypertension. The mean change of systolic and diastolic BP from baseline to 2 hours post-infusion on Cycle 1 Day 1 was 16.8 mmHg and 7.8 mmHg, respectively. The mean BP started decreasing approximately 2 hours post-infusion; BP remained elevated for 6 to 8 hours after the start of the ALIQOPA infusion. Optimal BP control should be achieved before starting each ALIQOPA infusion. Monitor BP pre- and post-infusion. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of hypertension [see Dosage and Administration ( 2.4 )] . 5.4 Non-Infectious Pneumonitis Non-infectious pneumonitis occurred in 5% of 317 patients treated with ALIQOPA monotherapy [see Adverse Reactions ( 6.1 )]. Withhold ALIQOPA and conduct a diagnostic examination of a patient who is experiencing pulmonary symptoms such as cough, dyspnea, hypoxia, or interstitial infiltrates on radiologic exam. Patients with pneumonitis thought to be caused by ALIQOPA have been managed by withholding ALIQOPA and administration of systemic corticosteroids. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of non-infectious pneumonitis [see Dosage and Administration ( 2.4 )] . 5.5 Neutropenia Grade 3 or 4 neutropenia occurred in 24% of 317 patients treated with ALIQOPA monotherapy. Serious neutropenic events occurred in 1.3% [see Adverse Reactions ( 6.1 )] . Monitor blood counts at least weekly during treatment with ALIQOPA. Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of neutropenia [see Dosage and Administration ( 2.4 )] . 5.6 Severe Cutaneous Reactions Grade 3 and 4 cutaneous reactions occurred in 2.8% and 0.6% of 317 patients treated with ALIQOPA monotherapy, respectively [see Adverse Reactions ( 6.1 )]. Serious cutaneous reaction events were reported in 0.9%. The reported events included dermatitis exfoliative, exfoliative rash, pruritus, and rash (including maculo-papular rash). Withhold, reduce dose, or discontinue ALIQOPA depending on the severity and persistence of severe cutaneous reactions [see Dosage and Administration ( 2.4 )] . 5.7 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, ALIQOPA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of copanlisib to pregnant rats during organogenesis caused embryo-fetal death and fetal abnormalities in rats at maternal doses as low as 0.75 mg/kg/day (4.5 mg/m 2 /day body surface area) corresponding to approximately 12% the recommended dose for patients. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for one month after the last dose [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )] .

Contraindications

4 CONTRAINDICATIONS None. None ( 4 ).

Common side effects

The most common adverse reactions (≥20%); Se reactions that occurred were pneumonia (8%); Pneumonitis (5%); And hyperglycemia (5%); Ons for dose reduction were hyperglycemia (7%); Neutropenia (5%); And hypertension (5%); For drug discontinuation were pneumonitis (2%)

Adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling. • Infections [see Warnings and Precautions ( 5.1 )] • Hyperglycemia [see Warnings and Precautions ( 5.2 )] • Hypertension [see Warnings and Precautions ( 5.3 )] • Non-infectious pneumonitis [see Warnings and Precautions ( 5.4 )] • Neutropenia [see Warnings and Precautions ( 5.5 )] • Severe cutaneous reactions [see Warnings and Precautions ( 5.6 )] The most common adverse reactions (≥20%) are hyperglycemia, diarrhea, decreased general strength and energy, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections, thrombocytopenia ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Bayer Healthcare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population. The safety data reflect exposure to ALIQOPA in 168 adults with follicular lymphoma and other hematologic malignancies treated with ALIQOPA 60 mg or 0.8 mg/kg equivalent in clinical trials. The median duration of treatment was 22 weeks (range 1 to 206 weeks). Serious adverse reactions were reported in 44 (26%) patients. The most frequent serious adverse reactions that occurred were pneumonia (8%), pneumonitis (5%) and hyperglycemia (5%). The most common adverse reactions (≥20%) were hyperglycemia, diarrhea, decreased general strength and energy, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections, and thrombocytopenia. Adverse reactions resulted in dose reduction in 36 (21%) and discontinuation in 27 (16%) patients. The most common reasons for dose reduction were hyperglycemia (7%), neutropenia (5%), and hypertension (5%). The most common reasons for drug discontinuation were pneumonitis (2%) and hyperglycemia (2%). Table 2 provides the adverse reactions occurring in at least 10% of patients receiving ALIQOPA monotherapy, and Table 3 provides the treatment-emergent laboratory abnormalities in ≥20% of patients and ≥4% of Grade ≥3 treated with ALIQOPA. Table 2: Adverse Reactions Reported in ≥10% of Patients with Follicular Lymphoma and Other Hematological Malignancies Treated with ALIQOPA ADVERSE REACTIONS ALIQOPA N = 168 Any Grade n (%) Grade 3 n (%) Grade 4 n (%) Metabolism and nutrition disorders Hyperglycemia 90 (54%) 56 (33%) 10 (6%) Blood and lymphatic system disorders Leukopenia 61 (36%) 20 (12%) 26 (15%) Neutropenia (including febrile neutropenia) 53 (32%) 16 (10%) 26 (15%) Thrombocytopenia 37 (22%) 12 (7%) 2 (1%) General disorders and administration site conditions Decreased general strength and energy (includes fatigue and asthenia) 61 (36%) 6 (4%) 0 Gastrointestinal disorders Diarrhea 60 (36%) 8 (5%) 0 Nausea 43 (26%) 1 (<1%) 0 Stomatitis (includes oropharyngeal erosion and ulcer, oral pain) 24 (14%) 3 (2%) 0 Vomiting 21 (13%) 0 0 Vascular disorders Hypertension (includes secondary hypertension) 59 (35%) 46 (27%) 0 Infections Lower respiratory tract infections (includes pneumonia, pneumonia bacterial, pneumonia pneumococcal, pneumonia fungal, pneumonia viral, pneumocystis jiroveci pneumonia, bronchopulmonary aspergillosis and lung infection) 35 (21%) 20 (12%) 3 (2%) Skin and subcutaneous tissue disorders Rash (includes exfoliative skin reactions) 26 (15%) 2 (1%) 1 (<1%) Additional adverse drug reactions reported at a frequency of <10% in patients with follicular lymphoma and other hematologic malignancies include pneumonitis (9%), mucosal inflammation (8%), and paresthesia and dysesthesia (7%). Table 3: Treatment-emergent Laboratory Abnormalities in ≥20% of Patients and ≥4% of Grade ≥3 Treated with ALIQOPA Laboratory Parameter ALIQOPA N = 168* Any Grade** n (%) Grade 3** n (%) Grade 4** n (%) Hematology abnormalities Decreased hemoglobin 130 (78%) 7 (4%) 0 Lymphocyte count decreased 126 (78%) 43 (27%) 4 (2%) White blood cell decreased 118 (71%) 30 (18%) 3 (2%) Platelet count decreased 109 (65%) 11 (7%) 3 (2%) Neutrophil count decreased 104 (63%) 20 (12%) 25 (15%) Serum chemistry abnormalities Hyperglycemia 160 (95%) 72 (43%) 9 (5%) Hypertriglyceridemia 74 (58%) 6 (5%) 0 Hypophosphatemia 72 (44%) 24 (15%) 0 Hyperuricemia 42 (25%) 40 (24%) 2 (1%) Serum lipase increased 34 (21%) 11 (7%) 2 (1%) *Denominator for each laboratory parameter may vary based on number of patients with specific numeric laboratory values available. **NCI-CTCAE v4.03

Dosage and administration

2 DOSAGE AND ADMINISTRATION • Recommended dosage: 60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Modify dosage for toxicity ( 2.1 , 2.4 ). • Reduce ALIQOPA dose to 45 mg in patients with moderate hepatic impairment (Child-Pugh B) or to 30 mg in patients with severe hepatic impairment (Child-Pugh C) ( 2.2 , 8.6 ). • See full prescribing information for important preparation and administration information ( 2.5 , 2.6 , 2.7 ). 2.1 Recommended Dosage The recommended dose of ALIQOPA is 60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Continue treatment until disease progression or unacceptable toxicity [see Warnings and Precautions ( 5 )] . 2.2 Dose Modification for Moderate or Severe Hepatic Impairment Reduce ALIQOPA dose to 45 mg in patients with moderate hepatic impairment (Child-Pugh B). Reduce ALIQOPA dose to 30 mg in patients with severe hepatic impairment (Child-Pugh C) [ see Use in Specific Populations ( 8.6 ) ]. 2.3 Dose Modification for Use with Strong CYP3A Inhibitors Reduce ALIQOPA dose to 45 mg if a strong CYP3A inhibitor must be used. Concomitant use of ALIQOPA with strong CYP3A inhibitors increases copanlisib exposure (AUC) and may increase the risk for toxicity [see Drug Interactions ( 7.1 )] . 2.4 Dosage Modifications for Toxicities Manage toxicities per Table 1 with dose reduction, treatment delay, or discontinuation of ALIQOPA. Discontinue ALIQOPA if life-threatening ALIQOPA-related toxicity occurs. Table 1: Dosage Modification and Toxicity Management a Toxicities Adverse Reaction Grade b Recommended Management Infections [see Warnings and Precautions ( 5.1 )] Grade 3 or higher Withhold ALIQOPA until resolution. Suspected pneumocystis jiroveci pneumonia (PJP) infection of any grade Withhold ALIQOPA. If confirmed, treat infection until resolution, then resume ALIQOPA at previous dose with concomitant PJP prophylaxis. Cytomegalovirus (CMV) infection or viremia of any grade Withhold ALIQOPA until infection or viremia resolves, then resume at previous dose. Hyperglycemia [see Warnings and Precautions ( 5.2 )] Pre-dose fasting blood glucose 160 mg/dL or more or random/non-fasting blood glucose of 200 mg/dL or more Withhold ALIQOPA until fasting glucose is 160 mg/dL or less, or a random/non-fasting blood glucose of 200 mg/dL or less. Pre-dose or post-dose blood glucose 500 mg/dL or more On first occurrence, withhold ALIQOPA until fasting blood glucose is 160 mg/dL or less, or a random/non-fasting blood glucose of 200 mg/dL or less. Then reduce ALIQOPA from 60 mg to 45 mg and maintain. On subsequent occurrences, withhold ALIQOPA until fasting blood glucose is 160 mg/dL or less, or a random/non-fasting blood glucose of 200 mg/dL or less. Then reduce ALIQOPA from 45 mg to 30 mg and maintain. If persistent at 30 mg, discontinue ALIQOPA. Hypertension [see Warnings and Precautions ( 5.3 )] Pre-dose blood pressure (BP) 150/90 or greater c Withhold ALIQOPA until BP is less than 150/90 based on two consecutive BP measurements at least 15 minutes apart. Post-dose BP 150/90 or greater c (non-life-threatening) If anti-hypertensive treatment is not required, continue ALIQOPA at previous dose. If anti-hypertensive treatment is required, consider reduction of ALIQOPA from 60 mg to 45 mg or from 45 mg to 30 mg. Discontinue ALIQOPA if BP remains uncontrolled (BP greater than 150/90) despite anti-hypertensive treatment Post-dose elevated BP with life-threatening consequences Discontinue ALIQOPA. Non-infectious pneumonitis (NIP) [see Warnings and Precautions ( 5.4 )] Grade 2 Withhold ALIQOPA and treat NIP. If NIP recovers to Grade 0 or 1, resume ALIQOPA at 45 mg. If Grade 2 NIP recurs, discontinue ALIQOPA. Grade 3 or higher Discontinue ALIQOPA. Neutropenia [see Warnings and Precautions ( 5.5 )] Absolute neutrophil count (ANC) 0.5 to 1.0 x 10 3 cells/mm 3 Maintain ALIQOPA dose. Monitor ANC at least weekly. ANC less than 0.5 x 10 3 cells/mm 3 Withhold ALIQOPA. Monitor ANC at least weekly until ANC 0.5 x 10 3 cells/mm 3 or greater, then resume ALIQOPA at previous dose. If ANC 0.5 x 10 3 cells/mm 3 or less recurs, then reduce ALIQOPA to 45 mg. Severe cutaneous reactions [see Warnings and Precautions ( 5.6 )] Grade 3 Withhold ALIQOPA until toxicity is resolved and reduce ALIQOPA from 60 mg to 45 mg or from 45 mg to 30 mg. Life-threatening Discontinue ALIQOPA. Thrombocytopenia [see Adverse Reactions ( 6.1 )] Less than 25 x 10 9 /L Withhold ALIQOPA; resume when platelet levels return to 75.0 x 10 9 /L or greater. If recovery occurs within 21 days, reduce ALIQOPA from 60 mg to 45 mg or from 45 mg to 30 mg. If recovery does not occur within 21 days, discontinue ALIQOPA. Other severe and non-life-threatening toxicities [see Adverse Reactions ( 6.1 )] Grade 3 Withhold ALIQOPA until toxicity is resolved and reduce ALIQOPA from 60 mg to 45 mg or from 45 mg to 30 mg. a Ensure a minimum of 7 days between any two consecutive infusions. b National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03. c Both systolic of less than 150 mmHg and diastolic of less than 90 mmHg are required. 2.5 Preparation and Administration For intravenous infusion only. Administer ALIQOPA as a single agent, following reconstitution and dilution. Mix only with sterile 0.9% Sodium Chloride Injection, USP solution. Do not mix or inject ALIQOPA with other drugs or other diluents. 2.6 Reconstitution Instructions Reconstitute ALIQOPA with 4.4 mL of sterile 0.9% Sodium Chloride Injection, USP solution leading to a concentration of 15 mg/mL. • Withdraw 4.4 mL of sterile 0.9% Sodium Chloride Injection, USP solution by using a 5 mL sterile syringe with needle. • Inject the measured volume through the disinfected stopper surface into the vial of ALIQOPA. • Dissolve the lyophilized solid by gently shaking the injection vial for 30 seconds. • Allow to stand for one minute to let bubbles rise to the surface. • Check if any undissolved substance is still seen. If yes, repeat the gentle shaking and settling procedure. • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. After reconstitution, the solution should be colorless to slightly yellowish. • Once the solution is free of visible particles, withdraw the reconstituted solution for further dilution. 2.7 Dilution Instructions for Intravenous Use Further dilute the reconstituted solution in 100 mL sterile 0.9% Sodium Chloride Injection, USP solution for injection. With a sterile syringe, withdraw the required amount of the reconstituted solution for the desired dosage: 60 mg: Withdraw 4 mL of the reconstituted solution with a sterile syringe. 45 mg: Withdraw 3 mL of the reconstituted solution with a sterile syringe. 30 mg: Withdraw 2 mL of the reconstituted solution with a sterile syringe. Inject the contents of the syringe into the patient infusion bag of 100 mL sterile 0.9% Sodium Chloride Injection, USP solution. Mix the dose well by inverting. Discard any unused reconstituted or diluted solution appropriately. Use reconstituted and diluted ALIQOPA immediately or store the reconstituted solution in the vial or diluted solution in the infusion bag at 2°C to 8°C (36°F to 46°F) for up to 24 hours before use. Allow the product to adapt to room temperature before use following refrigeration. Avoid exposure of the diluted solution to direct sunlight.

Drug interactions

7 DRUG INTERACTIONS • CYP3A Inducers: Avoid concomitant use with strong CYP3A inducers ( 7.1 ). • CYP3A Inhibitors: Reduce the ALIQOPA dose to 45 mg when concomitantly administered with strong CYP3A inhibitors ( 7.1 ). 7.1 Effect of Other Drugs on Copanlisib Table 4 lists the potential effects of coadministration of ALIQOPA with strong CYP3A inhibitors and inducers. Table 4: Drug Interactions with ALIQOPA that affect Copanlisib Concentrations Strong CYP3A inducers Clinical impact • Concomitant use of ALIQOPA with strong CYP3A inducers may decrease copanlisib AUC and C max [see Clinical Pharmacology ( 12.3 )] . Prevention management • Avoid concomitant use of ALIQOPA with strong CYP3A inducers Strong CYP3A inhibitors Clinical impact • Concomitant use of ALIQOPA with strong CYP3A inhibitors increases the copanlisib AUC [see Clinical Pharmacology ( 12.3 )] . • An increase in the copanlisib AUC may increase the risk of adverse reactions Prevention management • If concomitant use with strong CYP3A inhibitors cannot be avoided, reduce the ALIQOPA dose to 45 mg [see Dosage and Administration ( 2.3 )]

Common questions

What is Copanlisib approved to treat?

According to its FDA label, Copanlisib is approved for: 1 INDICATIONS AND USAGE ALIQOPA is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. Accelerated approval was granted for this indication based on overall response rate [see Clinical Studi… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Copanlisib?

Copanlisib belongs to the PI3K inhibitor class of medications.

What form does Copanlisib come in?

The FDA label lists Copanlisib as: 3 DOSAGE FORMS AND STRENGTHS For injection: 60 mg of copanlisib as a lyophilized solid in single-dose vial for reconstitution. For injection: 60 mg of copanlisib as a lyophilized solid in single-dose vial for reconstitution ( 3 ).. Available strengths and packaging vary by manufacturer.

Does Copanlisib have a Boxed Warning?

Our ingest of the FDA label for Copanlisib does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

Is Copanlisib currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Copanlisib in our latest ingest. Recall data can change daily — verify at FDA.gov.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…